Contents

Verteporfin versus ranibizumab for polypoidal choroidal vasculopathy (LAPTOP)

October 1, 2013

Clinical trial

Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results.

Oishi A, Kojima H, Mandai M, Honda S, Matsuoka T, Oh H, Kita M, Nagai T, Fujihara M, Bessho N, Uenishi M, Kurimoto Y, Negi A.

Am J Ophthalmol. 2013 Oct;156(4):644-51.
Full text | Metrics.

Main finding: Intravitreal ranibizumab is more effective than PDT for treatment-naive PDT

 

  • Purpose: To compare photodynamic therapy and intravitreal ranibizumab in PCV
  • Study type: Randomized controlled trial
  • Condition: Polypoidal choroidal vasculopathy

Participants: ≥50 years, active CNV (PCV and non-PCV included) secondary to AMD, VA 20/32-20/320

 

  • n=93

 

Intervention:

 

Group 1: Verteporfin PDT x 1 initially then PRN
Group 2: Intravitreal ranibizumab 0.5mg monthly x 3 then PRN

Outcome PDT RAN
VA gain 17.0% 30.4%
No change 55.0% 60.9%
VA loss 27.7% 8.7%

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2024 - sourceshed